Moteur de recherche d’entreprises européennes
Financement de l’UE (2 870 359 €) : Cibler la neuroinflammation pour lutter contre la douleur pathologique dans les maladies neurodégénératives et les syndromes douloureux chroniques Hor01/08/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Cibler la neuroinflammation pour lutter contre la douleur pathologique dans les maladies neurodégénératives et les syndromes douloureux chroniques
Damage to the central (CNS) and peripheral (PNS) nervous systems causes altered perception of pain (pathological pain) which is a common feature of diseases that have high prevalence in the European Union. Both increases and decreases in the ability to perceive pain impair both performance at work and quality of life. Pathological pain in neurodegenerative diseases, musculoskeletal diseases and peripheral neuropathies is associated with neuroinflammation, the inflammatory process whereby non-neuronal (inflammatory and glia) cells interact with neurones by releasing molecules that modulate pain signalling. TOBeATPAIN suggest that neuroinflammation represents an underlying mechanism of pathological pain states encompassing those with a PNS or CNS origin. The focus of this ITN will be on the mechanisms by which non-neuronal cells impact on neuronal activity in order to identify innovative non-neuronal targets for the treatment of pathological pain in peripheral macrophages or CNS microglia/astrocytes. TOBeATPAIN delivers high-level scientific and innovation-oriented complementary training, forging career pathways to increase inter-sectorial and transnational employability of young entrepreneurially-minded scientists in the academic and industrial sectors. It combines the expertise of 5 leading academic institutions, 2 pharmaceutical companies and 1 SME as Beneficiaries, together with 2 SMEs and 1 non-profit research charity as Partner Organisations, from 4 European countries. Fully aligned with the ‘Knowledge Triangle’ (business, research, higher education) platform, eleven ESRs will gain valuable knowledge and multidisciplinary skills through interdisciplinary research projects that integrate state-of-the-art technologies, supervision by and secondments to industrial Network organisations, Network-wide and local training activities, and specialized transferable skills focused in the acquisition of the ‘3-Knowledges’ (K-creation, K-exploitation, K-communication).
| Bionorica Research GmbH | 255 934 € |
| Eli Lilly and Company Ltd. | 91 096 € |
| Kancera AB | 263 659 € |
| Karolinska Institutet | 527 319 € |
| King's College London | 728 768 € |
| Medizinische Universitat Innsbruck | 255 934 € |
| Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat | 249 216 € |
| Universitatsklinikum Jena | 498 433 € |
https://cordis.europa.eu/project/id/764860
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
